Waltermire Robert E. has filed 30 insider transactions across 1 company since January 2024.
Most recent transaction: a option exercise of 6825 shares of MADRIGAL PHARMACEUTICALS, INC. ($MDGL) on March 05, 2025.
Activity breakdown: 0 open-market purchases and 16 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Common Stock | 6825 | $87.92 | 10,553.0000 | 22,080,246 | 183.07% | 0.03% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Common Stock | 7288 | $87.09 | 17,841.0000 | 22,080,246 | 69.06% | 0.03% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 900 | $335.15 | 16,941.0000 | 22,080,246 | 5.04% | 0.00% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1777 | $336.78 | 15,164.0000 | 22,080,246 | 10.49% | 0.01% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1146 | $338.09 | 14,018.0000 | 22,080,246 | 7.56% | 0.01% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 400 | $339.68 | 13,618.0000 | 22,080,246 | 2.85% | 0.00% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1657 | $340.75 | 11,961.0000 | 22,080,246 | 12.17% | 0.01% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1043 | $341.84 | 10,918.0000 | 22,080,246 | 8.72% | 0.00% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1077 | $342.90 | 9,841.0000 | 22,080,246 | 9.86% | 0.00% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 4701 | $343.85 | 5,140.0000 | 22,080,246 | 47.77% | 0.02% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1412 | $344.76 | 3,728.0000 | 22,080,246 | 27.47% | 0.01% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | A | Common Stock | 2061 | $0.00 | 5,789.0000 | 22,080,246 | 55.28% | 0.01% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Stock Option (Right to Buy) | 6825 | $0.00 | 4,375.0000 | 22,080,246 | 60.94% | 0.03% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Stock Option (Right to Buy) | 7288 | $0.00 | 3,062.0000 | 22,080,246 | 70.42% | 0.03% |
| March 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | A | Stock Option (Right to Buy) | 1157 | $0.00 | 1,157.0000 | 22,080,246 | 9999.99% | 0.01% |
| Feb. 28, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1052 | $340.99 | 3,903.0000 | 22,080,246 | 21.23% | 0.00% |
| Feb. 28, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 175 | $341.55 | 3,728.0000 | 22,080,246 | 4.48% | 0.00% |
| Jan. 24, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 103 | $335.24 | 4,955.0000 | 0 | 2.04% | 0.00% |
| Jan. 17, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 442 | $273.41 | 5,058.0000 | 0 | 8.04% | 0.00% |
| June 14, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Common Stock | 1900 | $87.09 | 7,400.0000 | 0 | 34.55% | 0.00% |
| June 14, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1900 | $280.00 | 5,500.0000 | 0 | 25.68% | 0.00% |
| June 14, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Stock Option (Right to Buy) | 1900 | $0.00 | 10,350.0000 | 0 | 15.51% | 0.00% |
| June 12, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Common Stock | 2000 | $87.92 | 7,500.0000 | 0 | 36.36% | 0.00% |
| June 12, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 2000 | $285.00 | 5,500.0000 | 0 | 26.67% | 0.00% |
| June 12, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | M | Stock Option (Right to Buy) | 2000 | $0.00 | 15,200.0000 | 0 | 11.63% | 0.00% |
| May 21, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | S | Common Stock | 1036 | $231.34 | 5,500.0000 | 0 | 15.85% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | A | Common Stock | 1419 | $0.00 | 6,536.0000 | 0 | 27.73% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | A | Stock Option (Right to Buy) | 2138 | $0.00 | 2,138.0000 | 0 | 9999.99% | 0.00% |
| Jan. 23, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | A | Market Stock Unit | 1419 | $0.00 | 1,419.0000 | 0 | 9999.99% | 0.00% |
| Jan. 16, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | F | Common Stock | 550 | $243.92 | 5,117.0000 | 0 | 9.71% | 0.00% |